Congo’s Ebola trials ask two different questions: can drugs prevent infection and save patients?
A new enrollment milestone highlights the difference between preventing illness after exposure and treating confirmed Bundibugyo disease.
Researchers confronting Congo's Ebola outbreak are testing more than one route to reducing its toll: preventing illness after exposure and improving survival once infection has been confirmed.
More than 250 people had enrolled in a prevention study by October 3, the Associated Press reported from Rwampara. Coordinated by the medical nonprofit ALIMA, the trial aims to recruit nearly one thousand adults and children over twelve who encountered a confirmed case within five days but have no symptoms.
Enrollment is a research milestone, not evidence that the drug works. The study must establish whether an intervention changes outcomes rather than merely recording that participants received it.
A separate effort addresses people already diagnosed with Bundibugyo virus disease, the form of Ebola involved in the current outbreak. WHO announced the opening of the PARTNERS treatment trial in July, testing the monoclonal antibody MBP134 and the antiviral remdesivir, as well as whether their combination offers additional benefit.
The randomized, controlled study is coordinated with Congo's Institut National de Recherche Biomédicale, Belgium's Institute of Tropical Medicine and the University of Oxford. Patients also receive supportive care, including fluids and management of oxygen, blood pressure and pain where needed.
WHO says the platform design allows other treatments to be added following scientific assessment, and an independent board reviews safety and study data. These features are intended to generate evidence during an outbreak rather than wait for it to end.
The distinction between the studies is fundamental. A prevention trial in exposed people without symptoms does not answer the same question as a treatment trial in confirmed patients. Success in one setting cannot simply be assumed in the other.
The virus itself adds another constraint. In May, WHO advisers recommended prioritizing candidate treatments for evaluation against Bundibugyo and identified possible vaccines for further research. Treatments developed for other Ebola viruses cannot automatically be described as effective against this one.
The history of Ebola research shows why that caution matters. A randomized trial during Congo's earlier outbreak enrolled 681 patients and found two antibody treatments superior to the comparison treatment, leading to changes in assignment after an interim review. That evidence concerned a different Ebola virus and does not establish the outcome of today's Bundibugyo studies.
